Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

143 results about "Stimulant" patented technology

Stimulants (also often referred to as psychostimulants or colloquially as uppers) is an overarching term that covers many drugs including those that increase activity of the central nervous system and the body, drugs that are pleasurable and invigorating, or drugs that have sympathomimetic effects. Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. The most frequently prescribed stimulants as of 2013 were lisdexamfetamine, methylphenidate, and amphetamine. It is estimated that the percentage of the population that has abused amphetamine-type stimulants (e.g., amphetamine, methamphetamine, MDMA, etc.) and cocaine combined is between 0.8% and 2.1%.

Crystal form of thyroid hormone receptor stimulant as well as preparation method and application of crystal form

The invention aims to provide a crystal form of a thyroid hormone receptor agonist, a preparation method, a pharmaceutical composition and application of the crystal form in preparation of a TRbeta selective agonist medicine. Compared with the prior art, the crystal form provided by the invention has one or more improved properties, and is of great significance to further development of the medicine.
Owner:CHENGDU HONGDA PHARM CO LTD

Pharmaceutical composition containing PGI2 receptor stimulant and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition containing a PGI2 receptor stimulant and application of the pharmaceutical composition. The pharmaceutical composition formed by combining the PGI2 receptor agonist compound shown in the general formula I or the pharmaceutical salt thereof and sildenafil has a synergistic effect on inhibiting K < + > induced pulmonary artery ring tension increase and / or inhibiting PDGF induced human pulmonary artery smooth muscle cell proliferation; the drug combination pharmaceutical composition is more helpful for treating diseases of patients with pulmonary arterial hypertension which cannot be controlled by a single drug. The synergistic effect of the combined drug composition on inhibition of K < + > induced pulmonary artery ring tension increase and / or inhibition of PDGF induced human pulmonary artery smooth muscle cell proliferation under a specific ratio and a test concentration is stronger than the synergistic effect of the existing drug composition selexipag and sildenafil. Therefore, the drug combination pharmaceutical composition with a specific proportion and a test concentration is more beneficial to treatment of diseases of moderate and severe pulmonary hypertension patients whose conditions cannot be controlled by the existing drug combination of selexipag and sildenafil.
Owner:SHIJIAZHUANG NO 4 PHARMACEUTICAL CO LTD +1

Olfactory delivery scaffolds and methods for making and using same

PCT designated stage expiredWO2025096244A1Organic active ingredientsSugar derivativesDiseaseStimulant
Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a "therapeutic component"), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.
Owner:OLFERA

Olfactory Delivery Scaffolds Using Peptides and Methods for Making and Using Same

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.
Owner:OLFERA

Preparation composition of glucagon-like peptide-1 receptor agonist administrated through nasal mucosa, preparation method, application and nasal applicator

The invention provides a preparation composition of a glucagon-like peptide-1 receptor agonist for nasal mucosa administration, and particularly relates to the technical field of biological medicine materials. The preparation composition mainly comprises a glucagon-like peptide-1 receptor stimulant, alkyl glycoside and phospholipid, wherein the ratio of the glucagon-like peptide-1 receptor stimulant to the alkyl glycoside to the phospholipid is (0.25-17.5): (0.25-10): (0.1-10) by mass. The active pharmaceutical ingredients in the preparation composition provided by the invention are delivered through nasal mucosa, directly enter blood circulation from an absorption part, can take effect quickly, have higher bioavailability, and improve the compliance of patients.
Owner:SHANGHAI WORLD LEADER PHARM CO LTD

System and method for delivering a therapy and sensing a biological activity in the mouth

Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (TST) and tongue position sensor (TSE) is provided, according to certain aspects. According to another aspect, a stimulus is delivered to the mouth and / or tongue via a mouthpiece secured to the subject's teeth. In another regard, a stimulus is delivered that generates a natural response to eliminate or reduce sleep disorders, such as for example at least one of snoring and obstructive sleep apnea.
Owner:SPLIT ROCK SCI INC

Application of alpha-melanocyte stimulant in treating asthma by inhibiting type II innate lymphocytes

The invention provides an application of alpha-melanocyte stimulant in treating asthma by inhibiting type II innate lymphocytes. An IL-7R-STAT pathway in activated lung ILC2 is inhibited through an alpha-MSH-MC5R axis, it is found that the neuroendocrine hormone alpha-MSH can target ILC2 to limit lung inflammation, and screening of new drugs for treating lung inflammation is facilitated.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Preparation method and application of impurity of beta 2 adrenal receptor agonist and M receptor antagonist bifunctional active compound

The invention belongs to the technical field of chemical pharmacy, and particularly relates to a preparation method and application of an impurity of a beta2 adrenal receptor stimulant and M receptor antagonist bifunctional active compound. According to the impurity preparation method of the beta2 adrenal receptor stimulant and M receptor antagonist bifunctional active compound, acetylation of amino is successfully realized by using acetylation reagents such as acetyl chloride and alkali accelerators such as N, N-diisopropylethylamine, then debenzylation is performed through hydrogenation reaction, and the compound shown in the formula I is successfully prepared. Then, through liquid chromatography purification, a high-purity compound as shown in the formula I is obtained, and the raw material medicine as shown in JKN2304 can meet the requirements of reference substances in the research and development process; the technical problem that in the prior art, an impurity synthesis process of a beta 2 adrenal gland receptor agonist and M receptor antagonist bifunctional active compound is lacked is solved.
Owner:XINXIANG HAIBIN PHARMA +1

Responsive hydrogel loaded with bionic nano-vesicles as well as preparation method and application of responsive hydrogel

The invention relates to responsive hydrogel loaded with bionic nano-vesicles as well as a preparation method and application of the responsive hydrogel, and belongs to the technical field of medical hydrogel. The method comprises the steps that odontogenic mesenchymal stem cells are stimulated by a chemical vesicle stimulant and then mixed with melatonin mother liquor for extrusion, the bionic nano vesicles are obtained, the chemical vesicle stimulant contains a buffer solution, a dithiothreitol solution and a paraformaldehyde solution, and the buffer solution contains 8.5-9 g / L of sodium chloride, 0.2-0.24 g / L of calcium dichloride and 2.3-2.4 g / L of 4-hydroxyethyl piperazine ethanesulfonic acid; 6-arm-PEG-pp-NH2 coupled with polypeptide capable of being cut by matrix metalloproteinase, six-arm polyethylene glycol succinimide glutarate and the bionic nano-vesicle are prepared into a first precursor solution and a second precursor solution respectively, the first precursor solution and the second precursor solution are mixed and subjected to standing to form gel, and the responsive hydrogel is prepared. According to the invention, the responsive hydrogel capable of obviously enhancing bone regeneration capacity is obtained.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY +1

Application of combined adenosine A1 receptor stimulant and dopamine D2 receptor stimulant in preparation of medicine or food for preventing oxygen poisoning of central nervous system

The invention relates to the technical field of medicines, in particular to application of combination of an adenosine A1 receptor stimulant and a dopamine D2 receptor stimulant in preparation of a medicine or food for preventing oxygen poisoning of a central nervous system. The invention provides a new application of a combined adenosine A1 receptor stimulant and a dopamine D2 receptor stimulant. Animal experiments prove that the combined adenosine A1 receptor stimulant CCPA and the dopamine D2 receptor stimulant bromocriptine can effectively delay the oxygen poisoning phenomenon of a central nervous system. Compared with the traditional method for preventing oxygen only by strictly limiting the pressure and time of oxygen inhalation, the method provided by the invention can be used for inhaling oxygen for a longer time under higher pressure, so that the application of hyperbaric oxygen in diving and hyperbaric medicine is further expanded.
Owner:CHINESE PEOPLES LIBERATION ARMY NAVAL SPECIALTY MEDICAL CENT

Compositions containing a non-caffeine stimulant or nootropic and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Disclosed herein are compositions that include a combination of: (1) a non-caffeine stimulant or nootropic (e.g., paraxanthine); (2) a ketone body or ketone body precursor, such as beta-hydroxybutyrate (BHB) salt, BHB ester, BHB acid, acetoacetate salt, acetoacetate ester, acetoacetic acid, 1,3-butanediol, medium chain fatty acid, or ester of medium chain fatty acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. The composition may include a vasodilator. The composition may include a short or medium chain fatty acid or ester thereof in addition to or instead of the ketone body or ketone body precursor. The composition can provide enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. The composition can also beneficially increase resting energy expenditure (resting metabolic rate), particularly when in a state of ketosis, enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy / lightheadedness when entering a ketogenic state.
Owner:AXCESS GLOBAL SCIENCES LLC

Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.
Owner:OLFERA

Drug to treat stimulant addiction

PCT designated stage expiredWO2025040956A2Organic active ingredientsNervous disorderWithdrawal syndromePharmacy medicine
Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.
Owner:RAUTIOLA DAVIN

Co-crystals or salts of psilocin and methods of treatment therewith

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.
Owner:RESET PHARMACEUTICALS INC

Pharmaceutical composition containing thyroxine receptor stimulant and folic acid substances

The invention provides a pharmaceutical composition. The pharmaceutical composition is composed of a thyroxine receptor beta agonist, folic acid substances and pharmaceutically acceptable auxiliary materials. The invention also relates to application of the composition in preparation of drugs for treating chronic fatty liver diseases. The pharmaceutical composition has the advantages that the pharmaceutical composition can be used for treating the fatty liver accompanied by hypothyroidism, and adverse reactions generated by independently taking a thyroid receptor beta agonist can be reduced.
Owner:SHENZHEN AUSA PHARM CO LTD +1

Pharmaceutical composition containing stimulant for PWAR5 expression as active ingredient for preventing or treating infectious diseases due to hepatitis c virus

The present invention relates to a pharmaceutical composition and the like containing a stimulant for PWAR5 expression as an active ingredient for preventing or treating infectious diseases due to hepatitis C virus, the present invention allowing the PWAR5 level to be sustained at a high level inside the cell to effectively inhibit proliferation of HCV.
Owner:VIEL-T INC

Compounds for treating psychostimulant misuse

Described herein are new dual sigma receptor and dopamine transporter small molecule antagonists. As these compounds are antagonists of both sigma receptors and dopamine transporters, these compounds dose-dependently antagonize stimulant self-administration and also diminish the effects of stimulant effects on dopamine level, thus indicating minimal abuse liability.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.
Owner:APHARMA

Residence structures and related methods

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and / or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and / or rapid dissolution / degradation in a physiological environment (e.g., intestinal environment) and / or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution / degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and / or enhancement agents with a structural material necessary for gastric residence but configured for controlled and / or tunable degradation / dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.
Owner:MASSACHUSETTS INST OF TECH +1

Cell proliferation detection kit

The invention relates to the technical field of cell detection kits, and particularly discloses a cell proliferation detection kit, which comprises: a base; the top seat is arranged above the base; the positioning assembly is connected with the partition plates and the top seat, so that the states of the partition plates can be conveniently adjusted, according to the cell proliferation culture requirements, drugs or irritants with different concentrations can be conveniently added into the reagent tubes, and an experimenter can move the top seat; the partition plates are simultaneously connected with the top seat and the base to form a parallelogram structure; the reagent tubes in the holes of the pore plate are inclined at the same time, so that an experimenter can add a reagent according to the reagent tubes which are inclined at the same time, the experiment process is simplified, the test efficiency is improved, the reagent is added by obliquely attaching the partition plate walls, bubbles can be prevented from being generated under the liquid level, and good wall attachment of the reagent is ensured; and the problems of aggregation and interference on experimental determination caused by severe oscillation of cells possibly caused by taking out the reagent tube are effectively avoided.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINZHOU MEDICAL UNIV

Regeneration of axons from novel ENPP1 inhibitors

A neurite growth stimulant is a small molecule ENPP1 inhibitor. Small molecule ENPP1 inhibitors are capable of treating central nervous system (CNS) injury and promoting axonal regeneration. The ENPP1 inhibitor in the carrier can be administered at damaged nerves and their cell bodies to promote the regeneration of axons.
Owner:THE HONG KONG UNIV OF SCI & TECH

Substance with anti-allergic activity and application thereof

The invention discloses a substance with anti-allergic activity and application thereof, the substance with anti-allergic activity is a bitter receptor stimulant, and the bitter receptor stimulant is selected from at least one of denatonium benzoate, difenidol and quinine. The compound can reduce the expression level of IgE in serum, inhibit mast cell degranulation and regulate and control expression of cytokines at the downstream of Th1, Th2 and Dc cells, so that allergy is prevented and allergic symptoms are relieved, and the compound can be used for preparing medicines, health foods, functional foods and dietary supplements for preventing and relieving food allergy.
Owner:ZHEJIANG GONGSHANG UNIVERSITY

Method for preparing biostimulant from hydrothermal carbonized liquid

The invention discloses a method for preparing a biostimulant from a hydrothermal carbonization solution. The method comprises the following steps: hydrothermal carbonization of biomass wastes, dilution of the hydrothermal carbonization solution, domestication of activated sludge and enhancement of synergistic functional bacteria, and aerobic treatment. The invention also discloses an application effect of the hydrothermal carbonization liquid. By means of the method, substances which are toxic to crop growth in the hydrothermal carbonization liquid can be effectively removed, a biostimulant functional product which has a promoting effect on crop growth is prepared, the technological process is green and environmentally friendly, the raw material adaptability is wide, the technology is stable, and good application prospects are achieved.
Owner:QINGDAO INST OF BIOENERGY & BIOPROCESS TECH CHINESE ACADEMY OF SCI

Method for detecting an immune cellular response

A method for detecting an immune cellular response including the steps of: (a) suctioning a defined amount of the sample by an automated suction / discharge device, (b) discharging this amount, using the device, into container R, containing, beforehand, at least one stimulant for secretion of the molecule by the at least one cell, or else not containing such a stimulant, (c) when the container does not contain the stimulant beforehand, introducing into container R the at least one secretion stimulant contained in container E, using the device, and (d) allowing the sample and stimulant to incubate, forming a mixture, by the at least one cell (i) in container R or (ii) in another container S after suctioning and discharge of the mixture using the device, and (e) detecting the immune cellular response, the detection of the immune cellular response indicates the presence of an immune cellular response specific for the stimulant.
Owner:BIOMERIEUX SA

Medicine with effects of drug rehabilitation and relapse prevention as well as preparation method and application of medicine

PendingCN120478353AOrganic active ingredientsNervous disorderChemical synthesisPsychoactive substance
The invention relates to a medicine with drug rehabilitation and relapse prevention effects as well as a preparation method and application thereof, and belongs to the field of medicines. The medicine comprises rotundine and salts and is prepared through a chemical synthesis method, and experiments prove that the medicine preparation has the effects of treating opioid substances including heroin, morphine, dolantin, methadone and the like as well as other psychoactive substances, such as opioid and the like. Independent or addiction formed by cocaine, amphetamine stimulants, wine, smoke, cannabis sativa, sedative and hypnotic drugs and the like has the effects of detoxifying, relieving symptoms, inhibiting psychological craving and reducing relapse rate.
Owner:SHANGHAI YIJIE BIOTECHNOLOGY CO LTD

Traditional Chinese medicine instant granules as well as preparation method and application thereof

The invention discloses traditional Chinese medicine instant granules as well as a preparation method and application thereof. The traditional Chinese medicine instant granules are prepared from the following raw materials in parts by mass: 20-60 parts of traditional Chinese medicine components, 60-200 parts of a filling agent, 20-60 parts of a disintegrating agent and 5-30 parts of an adhesive. Different from traditional soluble granules, on one hand, the moisturizing-free instant granules are used for oral administration without a large amount of solvent, can be quickly dissolved in a very small amount of water, and can be almost completely dissolved within 5 seconds to form tiny granules; on the other hand, saliva irritants are not needed. The traditional Chinese medicine instant granules take traditional Chinese medicines as medicinal components, can contain various natural herbaceous plant micro powder or extracts, such as platycodon grandiflorum, liquorice and other components with the effects of relieving cough, eliminating phlegm, diminishing inflammation, easing pain and the like, and can directly act on the throat mucosa; and the ginseng, the astragalus membranaceus and other components with the effects of regulating immunity, tonifying middle-Jiao and Qi and the like can be quickly dissolved and then effectively absorbed.
Owner:UNIV OF MACAU

Nano odontogenic mesenchymal stem cell vesicle as well as preparation method and application thereof

The invention relates to a nano odontogenic mesenchymal stem cell vesicle as well as a preparation method and application thereof, and belongs to the technical field of regenerative medicine and drug carriers. The method comprises the following steps: obtaining odontogenic mesenchymal stem cells; adding a chemical vesicle stimulant and then putting the mixture into a CO2 constant-temperature incubator for stimulation to obtain a giant plasma membrane vesicle solution of the odontogenic mesenchymal stem cells; repeatedly extruding through a polycarbonate film by using a lipidosome extruder to obtain the nano odontogenic mesenchymal stem cell vesicles of which the particle sizes are less than or equal to 200nm; the chemical vesicle stimulant comprises a buffer solution, a dithiothreitol aqueous solution and a paraformaldehyde solution, wherein the buffer solution comprises 8.5-9 g / L of sodium chloride, 0.2-0.24 g / L of calcium dichloride, 2.3-2.4 g / L of 4-hydroxyethyl piperazine ethanesulfonic acid and water. The obtained vesicles are high in yield and purity, have efficient bone tissue targeting property, and can prolong the in-vivo circulation time of the medicine and enhance the bone regeneration capacity.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY +1

Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).
Owner:TEMPERO BIO INC